A Method to Inhibit NF-kB and Managing Hemophilia

You are here

COVID-19 Response: Local Logistics     National Effort

The Novel Technology:

 
This novel method allows the identification of the molecular regulators that are triggering blood induced joint damage in severe hemophilia.
 
Applications: 
  • To obtain novel information on patho-biology of joint damage in one of the common genetic disorders, hemophilia A
  • To identify novel NF-kB or dependent targets to intervene with the development of synovitis and arthropathy in hemophilia
Advantages:
  • Specifically targets inflammatory or chondro-degenerative processes in the joints by blocking local activation of NF-κB using either shRNA directed against NF-κB or delivering anti-inflammatory targets using a NF-κB responsive promoter system.
  • Wide application in both haemophilia A and haemophilia B (in case of NF-kB dependent joint damage causing joint destruction)
Business Model:
 
The technology is at an early-stage of development with data showing that distinct members of the NF-κB (NF-κB1, NF-κB2, RelA, RelB), NF-κB -responsive inflammatory cytokine genes (IL-1b, IL-6, IFNg), HIF-1a, VEGF-1 and matrix metalloproteinase-13 are significantly (>2 fold) up-regulated in hemarthrotic Vs control joints. Looking for potential licensee(s) for further development of the technology. 
 
Principal Investigator(s): Dr. Jayandharan, CMC
 
Invention ID: CMP-024
 
IP Status: Patent Pending
 
Jurisdictions: India (IN) 
 
For more details, please write to:
techtransfer @ ccamp.res.in